Sky Pharma Co.,Ltd. is engaged in the research and development of drug discovery for diseases and injuries for which complete recovery is considered difficult at present, including glaucoma and spinal cord injury. Our aim is to realize regenerative medicine using low molecular size compounds, which is expected to allow mass production at a lower cost than biological products developed from iPS cells and other materials, which is currently the mainstream in regenerative medicine.
Capability for mass production helps to lower the unit cost, allowing the products to be delivered to more people.
From Tohoku to the World
The vision of Sky Pharma Co.,Ltd. is to establish a large-scale pharmaceutical company for research, discovery, and manufacture of cutting-edge regenerative medicine products.